新辅助化疗后手术治疗食管鳞癌的肿瘤反应。
Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery.
机构信息
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
出版信息
Anticancer Res. 2020 Feb;40(2):1153-1160. doi: 10.21873/anticanres.14057.
BACKGROUND/AIM: Neoadjuvant therapy followed by surgery is the standard treatment for advanced esophageal cancer. This study aimed to evaluated the potential of F-fluorodeoxyglucose positron-emission tomography to predict the pathological therapeutic effect of neoadjuvant chemotherapy.
PATIENTS AND METHODS
We enrolled 68 patients with advanced esophageal squamous cell carcinoma who underwent F-fluorodeoxyglucose positron-emission tomography before and after neoadjuvant chemotherapy, followed by surgery. Retrospective analysis of the pathological therapeutic effects was performed.
RESULTS
The pathological therapeutic effect of good responders was significantly inversely associated with the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy and with SUVmax reduction (both p<0.0001). Univariate and multivariate analyses revealed that lower post therapy SUVmax and reduction in SUVmax were independent prognostic factors for relapse-free (p=0.02) and overall survival (p<0.0001).
CONCLUSION
Post-neoadjuvant chemotherapy SUVmax and SUVmax reduction can predict the pathological therapeutic effect of neoadjuvant chemotherapy.
背景/目的：新辅助化疗后手术是治疗晚期食管癌的标准方法。本研究旨在评估 F-氟代脱氧葡萄糖正电子发射断层扫描预测新辅助化疗病理治疗效果的潜力。
患者与方法
我们纳入了 68 例接受新辅助化疗前后 F-氟代脱氧葡萄糖正电子发射断层扫描检查，随后进行手术的晚期食管鳞癌患者。对病理治疗效果进行回顾性分析。
结果
良好反应者的病理治疗效果与新辅助化疗后最大标准化摄取值（SUVmax）以及 SUVmax 降低呈显著负相关（均 p<0.0001）。单因素和多因素分析显示，治疗后 SUVmax 较低和 SUVmax 降低是无复发生存（p=0.02）和总生存（p<0.0001）的独立预后因素。
结论
新辅助化疗后 SUVmax 和 SUVmax 降低可预测新辅助化疗的病理治疗效果。
Zotero 插件